- Home
- SSB vs EXEL Comparison
SSB vs EXEL Comparison
Compare SSB & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SSB | EXEL |
|---|---|---|
| Founded | 1933 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6B | 11.1B |
| IPO Year | 1997 | 2000 |
Fundamental Metrics
Financial Performance| Metric | SSB | EXEL |
|---|---|---|
| Price | $107.27 | $43.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 22 |
| Target Price | ★ $118.92 | $46.24 |
| AVG Volume (30 Days) | 892.0K | ★ 2.6M |
| Earning Date | 01-22-2026 | 02-10-2026 |
| Dividend Yield | ★ 2.24% | N/A |
| EPS Growth | 12.91 | ★ 53.55 |
| EPS | ★ 7.87 | 2.38 |
| Revenue | ★ $2,561,294,000.00 | $2,288,218,000.00 |
| Revenue This Year | $9.40 | $9.47 |
| Revenue Next Year | $6.67 | $12.26 |
| P/E Ratio | ★ $13.62 | $18.49 |
| Revenue Growth | ★ 50.51 | 9.93 |
| 52 Week Low | $77.74 | $32.38 |
| 52 Week High | $108.46 | $49.62 |
Technical Indicators
Market Signals| Indicator | SSB | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 76.27 | 52.19 |
| Support Level | $99.24 | $42.17 |
| Resistance Level | $108.46 | $44.19 |
| Average True Range (ATR) | 2.50 | 1.41 |
| MACD | 0.55 | -0.01 |
| Stochastic Oscillator | 88.34 | 66.55 |
Price Performance
Historical ComparisonAbout SSB SouthState Corporation
SouthState Bank Corp is a United States-based bank holding company. It provides a wide range of services and products to its customers through a wholly-owned bank subsidiary. The Bank provides retail and commercial banking services, mortgage lending services, trust and investment services, and consumer finance loans through financial centers in Alabama, Florida, Georgia, North Carolina, South Carolina, and Virginia. These services include demand, time and savings deposits, lending and credit card servicing, ATM processing, and wealth management and trust services.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.